Table 4.
Assessment scores for prediction of the venous thromboembolic event-risk in cancer out-patients receiving chemotherapy, according to Khorana et al[73], Pabinger et al[75] and Verso et al[76]
| Khorana score criteria[73] | Score |
| Primary cancer | |
| With very high risk (pancreas, stomach) (high grade glioma1) | 2 |
| With high risk (lung, lymphoma, gynecologic, bladder, testicular) | 1 |
| Platelet count prior to chemotherapy > 350000/μL | 1 |
| Hb < 10 g/dL or ESA-application | 1 |
| Leukocyte count prior to chemotherapy > 11000/μL | 1 |
| Body mass index > 35 kg/m² | 1 |
| High risk | > 3 |
| Vienna prediction score (additional parameters to Khorana score)[75] | |
| D-dimer > 1.44 μg/mL | 1 |
| Soluble P-selectin > 153.1 μg/mL | 1 |
| High risk | > 4 |
| Protecht prediction score (additional parameters to Khorana score)[76] | |
| Cisplatin or carboplatin | 1 |
| Gemcitabine | 1 |
| High risk | > 3 |
1
High grade glioma are considered very high risk site of cancer in the Vienna prediction score only. ESA: Erythropoiesis stimulating agents.